Shopping Cart 0
Cart Subtotal
AED 0

Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376

Details

Valneva SE (VLA)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Valneva SE (Valneva) is a biotechnology company that develops lifesaving vaccines against infectious diseases and cancer. The company's products include a vaccine indicated for the prevention of Japanese encephalitis; and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of lyme, chikungunya, and zika viral infectious. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline vaccine candidates and to distribute its products. The company sells its products in the Americas, Asia Pacific, Europe and the Middle East. It operates in Austria, Sweden, the UK, France, Canada, and the US. Valneva is headquartered in Saint-Herblain, France.

Valneva SE Key Recent Developments

Jan 16,2019 VALNEVA Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

Jan 07,2019 VALNEVA announces its intention to delist from the vienna stock exchange

Nov 08,2018 VALNEVA reports nine month results for 2018, confirms guidance, strengthens balance sheet with EUR50m financing

Oct 16,2018 VALNEVA Announces Progress of Chikungunya Vaccine Candidate

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Valneva SE-Key Facts

Valneva SE-Key Employees

Valneva SE-Key Employee Biographies

Valneva SE-Major Products and Services

Valneva SE-History

Valneva SE-Company Statement

Valneva SE-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Valneva SE-Business Description

Product Category: Dukoral

Overview

Performance

Product Category: Ixiaro/Jespect

Overview

Performance

Key Stats

Product Category: Revenues from Collaborations, Licensing and Services

Performance

R&D Overview

Valneva SE-Corporate Strategy

Valneva SE-SWOT Analysis

SWOT Analysis-Overview

Valneva SE-Strengths

Valneva SE-Weaknesses

Valneva SE-Opportunities

Valneva SE-Threats

Valneva SE-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Valneva SE, Recent Deals Summary

Section 5-Company's Recent Developments

Jan 16, 2019: VALNEVA Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

Jan 07, 2019: VALNEVA announces its intention to delist from the vienna stock exchange

Nov 08, 2018: VALNEVA reports nine month results for 2018, confirms guidance, strengthens balance sheet with EUR50m financing

Oct 16, 2018: VALNEVA Announces Progress of Chikungunya Vaccine Candidate

Oct 05, 2018: VALNEVA Announces FDA Approval of Accelerated IXIARO Vaccination Schedule

Sep 20, 2018: Valneva announces extension of drawdown period for its existing european investment bank loan

Aug 02, 2018: VALNEVA Delivers Strong IXIARO Sales Growth and reports Further Progress on Key R&D Programs in H1

Jun 29, 2018: VALNEVA Announces Successful Outcome of its AGM and Renewal of the Term of Office of its Management Board Members

Jun 13, 2018: Valneva: Protecting unborn babies from Zika

May 17, 2018: VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Valneva SE, Performance Chart (2013-2017)

Valneva SE, Ratio Charts

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Valneva SE, Key Facts

Valneva SE, Key Employees

Valneva SE, Key Employee Biographies

Valneva SE, Major Products and Services

Valneva SE, History

Valneva SE, Other Locations

Valneva SE, Subsidiaries

Valneva SE, Key Competitors

Valneva SE, Ratios based on current share price

Valneva SE, Annual Ratios

Valneva SE, Annual Ratios (Cont...1)

Valneva SE, Interim Ratios

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Valneva SE, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Valneva SE, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Transgene SA

Themis Bioscience GmbH

Takeda Canada Inc

Innate Pharma SA

Gotovax AB

Globeimmune Inc

bioMerieux SA

Company Profile

Company Profile Title

Valneva SE (VLA)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Valneva SE (Valneva) is a biotechnology company that develops lifesaving vaccines against infectious diseases and cancer. The company's products include a vaccine indicated for the prevention of Japanese encephalitis; and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of lyme, chikungunya, and zika viral infectious. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline vaccine candidates and to distribute its products. The company sells its products in the Americas, Asia Pacific, Europe and the Middle East. It operates in Austria, Sweden, the UK, France, Canada, and the US. Valneva is headquartered in Saint-Herblain, France.

Valneva SE Key Recent Developments

Jan 16,2019 VALNEVA Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

Jan 07,2019 VALNEVA announces its intention to delist from the vienna stock exchange

Nov 08,2018 VALNEVA reports nine month results for 2018, confirms guidance, strengthens balance sheet with EUR50m financing

Oct 16,2018 VALNEVA Announces Progress of Chikungunya Vaccine Candidate

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Valneva SE-Key Facts

Valneva SE-Key Employees

Valneva SE-Key Employee Biographies

Valneva SE-Major Products and Services

Valneva SE-History

Valneva SE-Company Statement

Valneva SE-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Valneva SE-Business Description

Product Category: Dukoral

Overview

Performance

Product Category: Ixiaro/Jespect

Overview

Performance

Key Stats

Product Category: Revenues from Collaborations, Licensing and Services

Performance

R&D Overview

Valneva SE-Corporate Strategy

Valneva SE-SWOT Analysis

SWOT Analysis-Overview

Valneva SE-Strengths

Valneva SE-Weaknesses

Valneva SE-Opportunities

Valneva SE-Threats

Valneva SE-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Valneva SE, Recent Deals Summary

Section 5-Company's Recent Developments

Jan 16, 2019: VALNEVA Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

Jan 07, 2019: VALNEVA announces its intention to delist from the vienna stock exchange

Nov 08, 2018: VALNEVA reports nine month results for 2018, confirms guidance, strengthens balance sheet with EUR50m financing

Oct 16, 2018: VALNEVA Announces Progress of Chikungunya Vaccine Candidate

Oct 05, 2018: VALNEVA Announces FDA Approval of Accelerated IXIARO Vaccination Schedule

Sep 20, 2018: Valneva announces extension of drawdown period for its existing european investment bank loan

Aug 02, 2018: VALNEVA Delivers Strong IXIARO Sales Growth and reports Further Progress on Key R&D Programs in H1

Jun 29, 2018: VALNEVA Announces Successful Outcome of its AGM and Renewal of the Term of Office of its Management Board Members

Jun 13, 2018: Valneva: Protecting unborn babies from Zika

May 17, 2018: VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Valneva SE, Performance Chart (2013-2017)

Valneva SE, Ratio Charts

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Valneva SE, Key Facts

Valneva SE, Key Employees

Valneva SE, Key Employee Biographies

Valneva SE, Major Products and Services

Valneva SE, History

Valneva SE, Other Locations

Valneva SE, Subsidiaries

Valneva SE, Key Competitors

Valneva SE, Ratios based on current share price

Valneva SE, Annual Ratios

Valneva SE, Annual Ratios (Cont...1)

Valneva SE, Interim Ratios

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Valneva SE, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Valneva SE, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Transgene SA

Themis Bioscience GmbH

Takeda Canada Inc

Innate Pharma SA

Gotovax AB

Globeimmune Inc

bioMerieux SA